Log in

Relevant bibliographies by topics / Deoxypyridinoline / Journal articles

To see the other types of publications on this topic, follow the link: Deoxypyridinoline.

Journal articles on the topic 'Deoxypyridinoline'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 May 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Deoxypyridinoline.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Adamczyk, Maciej, Donald D. Johnson, Rajarathnam E. Reddy, and Sushil D. Rege. "Synthesis of isotopically labeled (+)-deoxypyridinoline." Journal of Labelled Compounds and Radiopharmaceuticals 43, no. 5 (April 2000): 463–72. http://dx.doi.org/10.1002/(sici)1099-1344(200004)43:5<463::aid-jlcr332>3.0.co;2-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rana Ali Hamdi. "Measurement of Serum Chemerin and Deoxypyridinoline Levels in Iraqi ‎Osteoporotic ‎Postmenopausal Women with and without Metabolic Syn-drome." International Journal of Research in Pharmaceutical Sciences 10, no. 2 (April 14, 2019): 1273–78. http://dx.doi.org/10.26452/ijrps.v10i2.420.

Full text

Abstract:

Metabolic syndrome is a cluster of medical conditions composed of ‎abdominal obesity, ‎hyperglycemia, hypertension, and lipid abnormalities, in which ‎each can affect bone in ‎different ways. We examine ‎the association between metabolic syndrome and metabolic bone disease ‎‎(osteoporosis) by ‎measuring adipose tissue marker (chemerin) and bone resorption ‎marker ‎‎(deoxypyridinoline) in ‎the serum of osteoporotic postmenopausal women with ‎and without ‎metabolic syndrome. ‎ A case-control study included 112 postmenopausal women from 51 to 67 years of ‎age. ‎Women were ‎selected from Osteoporosis Clinic- Al Yarmouk Teaching ‎Hospital and were ‎divided into two ‎groups: group (1)- patients group included 57 ‎postmenopausal women with ‎osteoporosis (35 ‎osteoporotic women with metabolic ‎syndrome and 22 osteoporotic women ‎without metabolic ‎syndrome) and group ‎‎(2)-control group included 55 postmenopausal women ‎without ‎osteoporosis and ‎metabolic syndrome. A serum sample was taken from each woman and ‎analysed ‎for ‎assessing chemerin, deoxypyridinoline, fasting serum glucose, and lipid profile. We found ‎a significant increase (p-value<0.001) in the mean value of serum chemerin ‎and ‎deoxypyridinoline ‎levels in patients compared to controls. ‎In ‎conclusion, chemerin is an adipose tissue marker associated with metabolic syndrome ‎and ‎may ‎have an impact on bone turn over and development of metabolic bone ‎disease ‎which ‎enhanced by the strong positive correlation between chemerin and bone ‎resorption ‎marker ‎‎(deoxypyridinoline).

APA, Harvard, Vancouver, ISO, and other styles

3

Macovei, Luana Andreea, Alexandra Burlui, and Elena Rezus. "Biochemical Markers of Bone Turnover in Rheumatoid Arthritis Patients Treated with Glucocorticoids." Revista de Chimie 70, no. 2 (March 15, 2019): 623–26. http://dx.doi.org/10.37358/rc.19.2.6970.

Full text

Abstract:

Osteocalcin and deoxypyridinoline levels were measured in 55 RA patients during and after glucocorticoid therapy with prednisone, methylprednisolone and cortisone. A decrease of 27% of the bone resorption marker deoxypyridinoline (from 10.13 to 7.4) and an increase of 23% of the bone formation marker osteocalcin (from 16.3 to 20.1) were also clinically confirmed by the presence of osteoporosis in 74% of patients receiving corticosteroid treatment as compared with only 31% in the control group.

APA, Harvard, Vancouver, ISO, and other styles

4

Kent, G. Neil. "Standardization of marker assays - pyridinoline/deoxypyridinoline." Scandinavian Journal of Clinical and Laboratory Investigation 57 (1997): 73–79. http://dx.doi.org/10.3109/00365519709168310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kent, G. Neil. "Standardization of marker assays - pyridinoline/deoxypyridinoline." Scandinavian Journal of Clinical and Laboratory Investigation 57, sup227 (January 1997): 73–79. http://dx.doi.org/10.1080/00365519709168310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Conti, A., S. Ferrero, S. Giambona, and A. Sartorio. "Urinary free deoxypyridinoline levels during childhood." Journal of Endocrinological Investigation 21, no. 5 (May 1998): 318–22. http://dx.doi.org/10.1007/bf03350335.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Eastell, Richard, Patricia S. Simmons, Antony Colwell, Adel M. A. Assiri, Mary F. Burritt, R. Graham, G. Russell, and B. Lawrence Riggs. "Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing." Clinical Science 83, no. 3 (September 1, 1992): 375–82. http://dx.doi.org/10.1042/cs0830375.

Full text

Abstract:

1. To investigate whether there is a nyctohemeral rhythm in bone turnover, we measured serum bone Gla-protein (osteocalcin, an index of osteoblast activity) concentration every 2 h and urinary deoxypyridinoline (a marker of bone collagen resorption) excretion for 8 h periods in 10 pubertal girls (aged 10–14 years), 15 premenopausal women (aged 20–49 years) and 17 postmenopausal women (aged 50–75 years). 2. The serum concentration of bone Gla-protein and the urinary excretion of deoxypyridinoline were five times higher in the pubertal girls than in the premenopausal women. The urinary excretion of deoxypyridinoline in the postmenopausal women was twice that in the premenopausal women. 3. There was a nyctohemeral pattern in all age groups with mean night-time increases of 28% (P<0.001) in the urinary excretion of deoxypyridinoline and of 5% (P<0.001) in the serum bone Gla-protein concentration. 4. There also were nyctohemeral patterns in the urinary excretion of calcium (P<0.02), sodium (P<0.001) and potassium (P<0.001), with decreases at night. There was a negative correlation between the night-time changes in the urinary excretion of deoxypyridinoline and calcium, especially in adult women (P<0.01). 5. The serum level of parathyroid hormone increased with age, but this effect was only observed at night (01.00 to 07.00 hours). There was a nyctohemeral rhythm of the serum intact parathyroid hormone level at all ages, with a peak in the afternoon and night. 6. Thus, at night, there is a large increase in bone resorption and a small increase in osteoblastic activity, representing a nyctohemeral rhythm of bone turnover. Although the amplitudes of bone formation and bone resorption are greater during growth, the pattern of nyctohemeral changes present during growth continues up to the age of 75 years.

APA, Harvard, Vancouver, ISO, and other styles

8

Robins, S. P., A. Duncan, N. Wilson, and B. J. Evans. "Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation." Clinical Chemistry 42, no. 10 (October 1, 1996): 1621–26. http://dx.doi.org/10.1093/clinchem/42.10.1621.

Full text

Abstract:

Abstract The collagen crosslinks, pyridinoline and deoxypyridinoline, have been developed as urinary markers of bone resorption but, despite wide clinical application of the technique, comparatively little attention has been paid to the standardization of these compounds. In this study, pyridinoline and deoxypyridinoline have been purified from bone and converted completely to monochloride trihydrochloride salts. In addition to mass spectrometry and NMR spectroscopy, the purity of the isolated materials was assessed by microelemental analysis including the chloride counterions. These purified compounds were used to establish individual molar absorptivity values as primary standardization criteria for the two crosslinks. For pyridinoline in 0.1 mol/L HCl, epsilon at 295 nm was 5490 L mol(-1) cm(-1); in 50 mmol/L sodium phosphate, pH 7.5, epsilon at 325 nm was 5785. The corresponding values for deoxypyridinoline at acid and neutral pH were 5160 and 5290 L mol(-1) cm(-1). The availability of standardization criteria for the crosslinks will allow more meaningful comparisons of clinical data between different laboratories.

APA, Harvard, Vancouver, ISO, and other styles

9

Jiang, Anqing, Yijie Liu, Xuefeng Li, Jie Chen, Heng Wang, Huilin Yang, and Weimin Jiang. "Serum osteocalcin and urinary free deoxypyridinoline as potential risk factors in predicting the prevalence of bone trauma among the post-menopausal Chinese women." Bangladesh Journal of Pharmacology 13, no. 3 (July 28, 2018): 231. http://dx.doi.org/10.3329/bjp.v13i3.36834.

Full text

Abstract:

<p>This study was designed to understand whether the post-menopausal Chinese women (n=175) receiving tablet containing vitamin D (500 IU) and calcium (500 mg) had lower incidence of bone fracture compared to the post-menopausal Chinese women ((n=175) receiving a diet rich in calcium, vitamin D, and protein (milk, cheese, and yogurt, soybeans, spinach, fish including fatty fish, cheese, egg). This study assessed whether the levels of serum osteocalcin and urinary free deoxypyridinoline could be used as predictors of early bone trauma during post-menopausal period. After randomization, subjects were followed-up for up to 3 years to capture required data. The results suggested that therapeutic intervention (vitamin D and calcium) does not predict bone fracture among the post-menopausal Chinese women. However, correlation analysis revealed that the decreased level of serum osteocalcin and urinary free deoxypyridinoline were associated with higher incidence of fracture. The results suggest that the low level of serum osteocalcin and urinary free deoxypyridinoline cause increase susceptibility of fracture among the post-menopausal Chinese women.</p>

APA, Harvard, Vancouver, ISO, and other styles

10

Tsuchiya, H., and C. J. Bates†. "Vitamin C and copper interactions in guinea-pigs and a study of collagen cross-links." British Journal of Nutrition 77, no. 2 (February 1997): 315–25. http://dx.doi.org/10.1079/bjn19970032.

Full text

Abstract:

The purpose of this study was, first to explore metabolic interactions between Cu and ascorbic acid in guinea-pigs, particularly with respect to any possible disadvantages of high ascorbatein the presence of low Cu intakes, and second, to test the hypothesis that variations in ascorbate and/or Cu status might inhence collagen cross-linking, either by inducing a change in thecross-links: hydroxyproline ratio, or by inducing a change in the pyridinoline: deoxypyridinoline cross-linls ratio. Four matched groups, each of eight male weanliig Dunkin-Hartley guinea-pigs, were maintained on purified diets containing either no added Cu, or 150 mg Cu/kg diet, and either 0·1 g or 30 g ascorbic acid/kg diet. They were then killed 8 weeks later, and the following indices were measured body and organ weights; blood haemoglobin; adrenal ascorbate concentrations; Cu concentrations in plasma, liver and femur; superoxide dismutase (EC 1.15.1.1) activity in whole blood and liver; hydroxyproline, pyridinoline and deoxypyridinoline in femur and in urine. The principal observations were: Cu intake significantly affected blood and tissue Cu concentrations and superoxide dismutase activity; and ascorbic acid intake significantlyaffected adrenal ascorbate levels and the deoxypyridinoline: pyridinoline cross-links ratio, especially in bone (femur). There was evidence of a significant interaction between ascorbateand Cu with respect to adrenal and plasma Cu concentrations, blood superoxide dismutase activityand body weights. We conclude that interactions between ascorbate and Cu at the functional level were present but modest, and that a new and potentially powerful functional index of ascorbate status may exist within the deoxypyridinoline: pyridinoliie collagen cross-link ratio.

APA, Harvard, Vancouver, ISO, and other styles

11

Adamczyk, Maciej, Donald D. Johnson, and Rajarathnam E. Reddy. "An efficient one-pot synthesis of (+)-deoxypyridinoline." Tetrahedron Letters 40, no. 51 (December 1999): 8993–94. http://dx.doi.org/10.1016/s0040-4039(99)01936-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Westhoff, B., R. Krauspe, A. E. Kalke, D. Hermsen, B. Kowall, R. Willers, and U. Schneider. "Urinary excretion of deoxypyridinoline in Perthes’ disease." Journal of Bone and Joint Surgery. British volume 88-B, no. 7 (July 2006): 967–71. http://dx.doi.org/10.1302/0301-620x.88b7.16564.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Shaw, N. J., J. Dutton, W. D. Fraser, and C. S. Smith. "Urinary pyridinoline and deoxypyridinoline excretion in children." Clinical Endocrinology 42, no. 6 (June 1995): 607–12. http://dx.doi.org/10.1111/j.1365-2265.1995.tb02687.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Seven, Özlem, Hale Karapolat, Sibel Eyigor, Yesim Kirazlı, and Berrin Durmaz. "Risk factors for osteoporosis in healthy males." Open Medicine 5, no. 5 (October 1, 2010): 593–600. http://dx.doi.org/10.2478/s11536-009-0111-9.

Full text

Abstract:

AbstractWe investigated the correlation of bone mineral density (BMD) with risk factors and laboratory parameters (e.g., markers of bone turnover, biochemical indicators, and hormonal factors) in males without secondary osteoporosis. A total of 105 males were divided into two groups: Group 1 (n: 52) <60 years, and Group 2 (n:53) ≥ 60 years. The subjects were evaluated for risk factors (European Vertebral Osteoporosis Study (EVOS) and BMD) and for biochemical (i.e., blood calcium, blood phosphorus, urinary calcium/phosphorus, creatinine clearance, osteocalcin, and deoxypyridinoline) and hormonal markers (follicle-stimulating hormone [FSH], luteinizing hormone [LH], free testosterone [fT], and parathyroid [PTH]) of bone mineral metabolism. In Group 1, no significant relationship was observed between risk factors for both lumbar and femoral neck BMDs and risk factors and laboratory parameters (p>0.05). On the other hand, we observed in Group 2 a significant positive correlation between lumbar BMD and BMI, BMI at 25 years of age, and fT; in the same group, a negative correlation between lumbar BMD and deoxypyridinoline (p<0.05) was seen. We saw a significant positive correlation between femoral neck BMD and BMI, BMI at 25 years of age, and daily activities of life in Group 2. In addition, we saw a negative correlation between femoral neck BMD and height difference, fT, LH, and deoxypyridinoline in Group 2 (p<0.05). Risk factors for male osteoporosis were multifactorial: demographic and clinical data (difference of height, BMI, physical activity) together with biochemical and hormonal data (deoxypyridinoline, fT, LH) were significant, and most of the risk factors analyzed were related to bone loss in the proximal femur.

APA, Harvard, Vancouver, ISO, and other styles

15

Kani, Tomiko, Chikao Miki, Hitoshi Tonouchi, Yuko Akehi, and Junko Ono. "Urinary excretion of deoxypyridinoline increases after gastrointestinal surgery." Nutrition 19, no. 9 (September 2003): 747–53. http://dx.doi.org/10.1016/s0899-9007(03)00096-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Soylu, H. "Urinary Free Deoxypyridinoline Assessment in Recognition of Rickets." Journal of Tropical Pediatrics 47, no. 3 (June 1, 2001): 186–87. http://dx.doi.org/10.1093/tropej/47.3.186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Alwaidh, M. H., W. B. Frazer, and W. S. Ryan. "Urinary Pyridinoline and Deoxypyridinoline excretion in VLBW infants." Pediatric Research 44, no. 3 (September 1998): 439. http://dx.doi.org/10.1203/00006450-199809000-00156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Milliken, L. A., A. D. Faigenbaum, R. Larosa Loud, and W. L. Westcott. "RELIABILITY OF DEOXYPYRIDINOLINE CROSSLINKS (DPD) MEASUREMENTS IN CHILDREN." Medicine & Science in Sports & Exercise 35, Supplement 1 (May 2003): S81. http://dx.doi.org/10.1097/00005768-200305001-00444.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Fineato, G., V. de Leonardis, G. Abbiati, M. L. Brandi, and F. Bartucci. "Urinary excretion of pyridinoline and deoxypyridinoline: Circadian rhythm." Bone and Mineral 17 (April 1992): 132. http://dx.doi.org/10.1016/0169-6009(92)91870-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ito, Junko, Toshiaki Tanaka, Reiko Horikawa, Mari Satoh, Sachiko Kitanaka, Ayako Tanae, Itsuro Hibi, Masakazu Miura, and Keishi Hata. "Urinary Excretion of Pyridinoline and Deoxypyridinoline in Children." Clinical Pediatric Endocrinology 7, no. 1 (1998): 47–52. http://dx.doi.org/10.1297/cpe.7.47.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Seamans, Kelly M., Tom R. Hill, Lisa Scully, Nathalie Meunier, Maude Andrillo-Sanchez, Angela Polito, Isabelle Hininger-Favier, et al. "Vitamin D Status and Indices of Bone Turnover in Older European Adults." International Journal for Vitamin and Nutrition Research 81, no. 5 (September 1, 2011): 277–85. http://dx.doi.org/10.1024/0300-9831/a000075.

Full text

Abstract:

An increased rate of bone turnover increases risk of osteoporotic fracture later in life. The concentration of 25-hydroxyvitamin D that contributes to an elevated rate of bone turnover in older adults is unclear. The objective of this study was to investigate the associations between 25-hydroxyvitamin D and biochemical markers of bone turnover in an older, pan-European cohort. 25-hydroxyvitamin D and serum markers of bone-formation (osteocalcin and bone-specific alkaline phosphatase) were assessed by ELISA, while urinary markers of bone-resorption (pyridinoline and deoxypyridinoline) were assessed by HPLC. Six percent, 36 %, and 64 % of subjects had 25-hydroxyvitamin D concentrations < 25, < 50, and < 80 nmol/L throughout the year, respectively. 25-hydroxyvitamin D was significantly and inversely correlated with serum bone-specific alkaline phosphatase (r = 0.119; p = 0.022) and urinary pyridinoline (r = 0.207; p < 0.0001) and deoxypyridinoline (r = 0.230; p < 0.0001). Stratification on the basis of tertiles [T] of 25-hydroxyvitamin D (< 47.6 [T1]; 47.6 - 85.8 [T2]; > 85.8 [T3] nmol/L), showed that urinary pyridinoline and deoxypyridinoline were significantly lower in subjects in the 2nd and 3rd compared to the 1st tertile (p < 0.015). Low vitamin D status (< 50 nmol/L) was associated with an increased rate of bone turnover in this older pan-European cohort.

APA, Harvard, Vancouver, ISO, and other styles

22

Shi, Jiandang, Zili Wang, Haomin Li, and Haifeng Yuan. "Diagnostic Performance of the Urinary Deoxypyridinoline in Spinal Tuberculosis." Orthopedics 35, no. 6 (June 1, 2012): e922-e926. http://dx.doi.org/10.3928/01477447-20120525-36.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Arican, M., Ö. Köylü, A. Uyaroglu, M. Erol, and K. N. Çalim. "Diagnostic Importance of Deoxypyridinoline and Osteocalcine in Equine Osteoarthritis." Acta Veterinaria Brno 73, no. 4 (2004): 491–96. http://dx.doi.org/10.2754/avb200473040491.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Schneider, Ulrich, Edward A. Schober, Nikolaus A. Streich, and Steffen J. Breusch. "Urinary creatinine instability falsely increases the deoxypyridinoline/creatinine quotient." Clinica Chimica Acta 324, no. 1-2 (October 2002): 81–88. http://dx.doi.org/10.1016/s0009-8981(02)00209-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rubinacci, Alessandro, Raffaella Melzi, Maria Zampino, Armando Soldarini, and Isabella Villa. "Total and Free Deoxypyridinoline after Acute Osteoclast Activity Inhibition." Clinical Chemistry 45, no. 9 (September 1, 1999): 1510–16. http://dx.doi.org/10.1093/clinchem/45.9.1510.

Full text

Abstract:

Abstract Background: Deoxypyridinoline (Dpd) is one of the two pyridinium cross-links that provide structural rigidity to type I collagen in bone. During osteoclastic resorption, Dpd is released into circulation and is excreted in the urine in free and peptide-bound forms. Free and total Dpd are highly correlated, but whether the free-to-total cross-link ratio is constant in both normal and high bone turnover states remains controversial. To compare free and total Dpd performance in a physiological condition, urinary free and total Dpd were measured after a short-term inhibition of osteoclast activity such as that induced by an oral calcium load. Methods: Total and free Dpd were measured by HPLC and by immunosorbent assay, respectively, in two groups of subjects, one (calcium-treated; n = 16) taking calcium and the other not (control; n = 9). Results: The urinary excretion of total Dpd at 2 and 4 h after oral calcium loading was decreased compared with controls. By contrast, changes in free Dpd were similar in the calcium-treated and control groups, reflecting only circadian rhythm. Conclusions: Total and free Dpd do not show comparable sensitivity in detecting short-term inhibition of osteoclast activity. The degradation process of peptide-bound to free Dpd could render free Dpd insensitive to acute changes of osteoclast activity.

APA, Harvard, Vancouver, ISO, and other styles

26

Adamczyk, Maciej, Donald D. Johnson, and Rajarathnam E. Reddy. "ChemInform Abstract: An Efficient One-Pot Synthesis of (+)-Deoxypyridinoline." ChemInform 31, no. 10 (June 10, 2010): no. http://dx.doi.org/10.1002/chin.200010174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Martin-de las Heras, S., A. Valenzuela, and E. Villanueva. "Deoxypyridinoline crosslinks in human dentin and estimation of age." International Journal of Legal Medicine 112, no. 4 (June 18, 1999): 222–26. http://dx.doi.org/10.1007/s004140050240.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Perepelyuk, Maryna, Masahiko Terajima, Andrew Y. Wang, Penelope C. Georges, Paul A. Janmey, Mitsuo Yamauchi, and Rebecca G. Wells. "Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury." American Journal of Physiology-Gastrointestinal and Liver Physiology 304, no. 6 (March 15, 2013): G605—G614. http://dx.doi.org/10.1152/ajpgi.00222.2012.

Full text

Abstract:

Liver fibrosis is characterized by excessive deposition of extracellular matrix proteins by myofibroblasts derived from hepatic stellate cells and portal fibroblasts. Activation of these precursors to myofibroblasts requires matrix stiffness, which results in part from increased collagen cross-linking mediated by lysyl oxidase (LOX) family proteins. The aims of this study were to characterize the mechanical changes of early fibrosis, to identify the cells responsible for LOX production in early injury, and to determine which cells in normal liver produce collagens and elastins, which serve as substrates for LOXs early after injury. Hepatocytes and liver nonparenchymal cells were isolated from normal and early-injured liver and examined immediately for expression of LOXs and matrix proteins. We found that stellate cells and portal fibroblasts were the major cellular sources of fibrillar collagens and LOXs in normal liver and early after injury (1 day after bile duct ligation and 2 and 7 days after CCl4 injury). Activity assays using stellate cells and portal fibroblasts in culture demonstrated significant increases in LOX family enzymatic activity as cells became myofibroblastic. LOX family-mediated deoxypyridinoline and pyridinoline cross-links increased after CCl4-mediated injury. There was a significant association between liver stiffness (as quantified by the shear storage modulus G′) and deoxypyridinoline levels; increased deoxypyridinoline levels were also coincident with significantly increased elastic resistance to large strain deformations, consistent with increased cross-linking of the extracellular matrix. These data suggest a model in which the liver is primed to respond quickly to injury, activating potential mechanical feed-forward mechanisms.

APA, Harvard, Vancouver, ISO, and other styles

29

Trebble, Timothy M., Mike A. Stroud, Stephen A. Wootton, Philip C. Calder, David R. Fine, Mark A. Mullee, Caje Moniz, and Nigel K. Arden. "High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial." British Journal of Nutrition 94, no. 2 (August 2005): 253–61. http://dx.doi.org/10.1079/bjn20051466.

Full text

Abstract:

Crohn's disease is associated with altered bone turnover that may be influenced by nutritional status, the systemic inflammatory response, cytokine production by circulating (peripheral blood) mononuclear cells (PBMC) and antioxidant micronutrient intake. High-dose fish oil is associated with reductions in disease relapse and inflammatory markers, and modulates PBMC function. The effect of fish oil plus antioxidants on bone turnover and PBMC function (the production of interferon-γ and prostaglandin E2) in Crohn's disease was investigated in a randomised-controlled trial. Patients with currently or recently raised biochemical markers of inflammation (C-reactive protein ≧6·9 mg/l or erythrocyte sedimentation rate ≧18 mm/h) received fish oil (providing 2·7 g/d EPA and DHA) and antioxidants (vitamins A, C and E, and Se) (n 31) or placebo (n 30) for 24 weeks. Bone turnover was assessed by measuring the concentrations of urinary deoxypyridinoline (bone resorption) and serum osteocalcin (bone formation). Fish oil plus antioxidants were associated with increases in EPA, DHA Se in plasma (all P<0·01), and with a reduction in interferon-γ production by mitogen-stimulated PBMC, which demonstrated a negative correlation with deoxypyridinoline/creatinine:osteocalcin ratio (r −0·33, P=0·009). There were no differences between the groups at 24 weeks in the response of deoxypyridinoline or osteocalcin or their ratio, or in nutritional status. Dietary supplementation in Crohn's disease with high intakes of EPA and DHA, as fish oil, plus antioxidants was associated with a modulated production of interferon-γ by PBMC but not altered indices of bone turnover.

APA, Harvard, Vancouver, ISO, and other styles

30

Caillot-Augusseau, Anne, Laurence Vico, Martina Heer, Dimitri Voroviev, Jean-Claude Souberbielle, Armin Zitterman, Christian Alexandre, and Marie-Hélène Lafage-Proust. "Space Flight Is Associated with Rapid Decreases of Undercarboxylated Osteocalcin and Increases of Markers of Bone Resorption without Changes in Their Circadian Variation: Observations in Two Cosmonauts." Clinical Chemistry 46, no. 8 (August 1, 2000): 1136–43. http://dx.doi.org/10.1093/clinchem/46.8.1136.

Full text

Abstract:

Abstract Background: Microgravity induces bone loss by mechanism(s) that remain largely unknown. Methods: We measured biochemical markers related to bone remodeling in two cosmonauts before, during, and after 21- and 180-day space flights, respectively. Results: During both flights, type I procollagen propeptide and bone alkaline phosphatase decreased as early as 8 days after launch. Undercarboxylated osteocalcin percentage increased early and remained high during both flights. Vitamin K supplementation restored carboxylation of osteocalcin during the long-term flight. Urinary and serum C-telopeptide of type I collagen (CTX) increased as early as day 8 of the flights; the increase was greater in serum than in urine. Pyridinoline, free deoxypyridinoline, and N-telopeptide increased less than CTX during the short-term space flight. The circadian rhythm of bone resorption assessed by urine CTX and free deoxypyridinoline was not altered by microgravity. Conclusion: Vitamin K metabolism or action and bone remodeling may be altered in cosmonauts.

APA, Harvard, Vancouver, ISO, and other styles

31

Tsuchiya, Harumi, and C. J. Bates. "Comparison of vitamin C deficiency with food restriction on collagen cross-link ratios in bone, urine and skin of weanling guinea-pigs." British Journal of Nutrition 89, no. 3 (March 2003): 303–10. http://dx.doi.org/10.1079/bjn2002775.

Full text

Abstract:

Mild-to-moderate vitamin C depletion in weanling guinea-pigs affects pyridinoline:deoxypyridinoline (collagen cross-link) ratios in femur shaft and urine, attributed to impairment of hydroxylation of collagen lysine. We investigated: (1) whether the picture at two time points is compatible with progressive accumulation of abnormal collagen; (2) whether any changes are seen in skin, where little deoxypyridinoline occurs; (3) whether total food restriction has similar effects. Male weanling Dunkin–Hartley guinea-pigs were fed diets containing either 0·5 (vitamin C-restricted) or 160·0–320·0 (vitamin C-adequate) mg vitamin /. Two groups receiving the vitamin C-adequate diet received it ad libitum. Two other groups received the vitamin C-adequate diet in a restricted amount, limited to that which permitted nearly the same growth rate as in the vitamin C-restricted groups. Animals were fed for 4 or 8 weeks; urine was collected, and vitamin C and collagen indices were measured. In the femur shaft, the hydroxyproline content per unit weight was unaffected by vitamin C restriction or by total food restriction. Deoxypyridinoline was increased and the pyridinoline:deoxypyridinoline ratio was decreased in vitamin C-restricted groups, but not in food-restricted groups. Changes in the value of the ratio were greater after 8 than after 4 weeks. Urine indices mirrored bone indices. In skin, the main effect of vitamin C restriction was to reduce hydroxyproline. Here, the cross-link ratios changed less markedly than in bone, and there was less deoxypyridinoline. We conclude that the picture at two time points is compatible with a progressive accumulation of pyridinoline-enriched collagen in vitamin C-deprived animals, that the picture in skin differs from that of bone and urine, and that cross-link changes are not produced by total food restriction.

APA, Harvard, Vancouver, ISO, and other styles

32

De Romero, Beatriz Cepeda, Diana Carolina Cañon Guarnizo, Lina Marcela Orozco Herrera, Sofìa Cepeda Tarazona, and Maria Alexandra Polo Pacheco. "Deoxypyridinoline bone height after oral implant surgery in menopause women." International Research Journal of Medicine and Medical Sciences 7, no. 2 (June 2019): 48–52. http://dx.doi.org/10.30918/irjmms.72.19.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Segawa, Yoshihide, Kenji Yoshida, Naoki Tuzuike, and Kazuo Matsuda. "Urinary deoxypyridinoline in the development of adjuvant-induced arthritis rats." Ensho 14, no. 4 (1994): 337–39. http://dx.doi.org/10.2492/jsir1981.14.337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Çakatay, Ufuk, Ayşegül Telci, Refik Kayalı, Tülay Akçay, Ahmet Sivas, and Ferihan Aral. "Changes in bone turnover on deoxypyridinoline levels in diabetic patients." Diabetes Research and Clinical Practice 40, no. 2 (May 1998): 75–79. http://dx.doi.org/10.1016/s0168-8227(98)00025-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Allevi, Pietro, Alessandra Longo, and Mario Anastasia. "Total synthesis of deoxypyridinoline, a biochemical marker of collagen turnover." Chemical Communications, no. 6 (1999): 559–60. http://dx.doi.org/10.1039/a900298g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rosano, Thomas G., Robert T. Peaston, Henry G. Bone, Henning W. Woitge, Roger M. Francis, and Markus J. Seibel. "Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation." Clinical Chemistry 44, no. 10 (October 1, 1998): 2126–32. http://dx.doi.org/10.1093/clinchem/44.10.2126.

Full text

Abstract:

Abstract We evaluated an automated chemiluminescence immunoassay (CLIA) developed for the measurement of urinary free deoxypyridinoline (DPD). The new DPD method by CLIA is based on the competition of DPD with particle-bound pyridinoline for a limited amount of monoclonal mouse anti-DPD antibody. Total imprecision (CV) was 3.2–9.0% at 30–270 nmol/L. Regression analysis of urinary DPD concentration (second morning-void) measured by CLIA (y) and enzyme immunoassay (EIA) for adult volunteers (n = 449) with and without bone disease revealed a best fit equation of: y = 1.08 ± 0.03x − 1.15 ± 0.98 nmol/L (r = 0.964, Sy‖x = 14 nmol/L). CLIA and EIA methods were correlated with HPLC measurement of urinary free DPD (r = 0.846 and 0.871, respectively). For healthy adults, the creatinine-normalized excretion of DPD (mean ± SD) measured by CLIA for 61 men (4.1 ± 1.2 μmol DPD/mol creatinine) and 76 premenopausal women (5.3 ± 1.8 μmol DPD/mol creatinine) did not differ significantly (P >0.05) from DPD excretion measured by EIA, and both immunoassays showed a significant gender difference (P <0.001) in reference intervals. In a clinical trial, DPD excretion (μmol DPD/mol creatinine) measured by CLIA differed substantially from the reference population for 54 untreated pagetic (12.7 ± 8.0 SD), 255 untreated osteoporotic (7.5 ± 4.1), 21 osteomalacic (12.4 ± 8.5), 17 primary hyperparathyroid (9.4 ± 4.4), and 14 secondary hyperparathyroid (9.2 ± 5.1) patients. Clinical sensitivities of the CLIA and EIA methods range from 38% to 80% in bone disorders and limit the use of the DPD measurement in disease detection. DPD excretion after pamidronate treatment in a subgroup of the pagetic patients fell dramatically as assessed by CLIA or EIA. We conclude that the automated CLIA method for DPD is a convenient and reliable method that may aid in the evaluation and management of bone disease and is applicable to high volume testing in the routine clinical laboratory.

APA, Harvard, Vancouver, ISO, and other styles

37

Adamczyk, Maciej, Donald D. Johnson, and Rajarathnam E. Reddy. "Collagen cross-links: Synthesis of pyridinoline, deoxypyridinoline and their analogues." Tetrahedron 55, no. 1 (January 1999): 63–88. http://dx.doi.org/10.1016/s0040-4020(98)01023-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Georgiadis, A. E., E. Georgiou, G. Douskas, and X. Vogiatzi. "Peculiar effect of nasal calcitonin on deoxypyridinoline(DPD) urinary excretion." Osteoporosis International 6, S1 (January 1996): 272. http://dx.doi.org/10.1007/bf02500624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Pohranychna, Kh R., A. R. Stasyshyn, and U. D. Matolych. "Early diagnostics of temporomandibular joint structural elements injures caused by traumatic mandibular bone fractures." Polish Journal of Surgery 89, no. 3 (June 30, 2017): 31–35. http://dx.doi.org/10.5604/01.3001.0010.1022.

Full text

Abstract:

A rapidly increasing number of mandibular condylar fractures and some complications related to injuries of temporomandibular elements make this study important. Intra-articular disorders lead to secondary pathological findings such as osteoarthritis, deforming osteoarthrosis, and temporomandibular joint ankylosis that limits mouth opening, mastication, swallowing, breathing, and decreased/lost working capacity or disability. Early diagnosis of intra-articular disorders can prevent from long-lasting functional complications caused by temporomandibular joint injuries. This study was performed for the purpose of early detection and investigation of organic pathological changes in the cartilaginous and osseous tissues of the temporomandibular joint caused by traumatic fractures of the mandibular condyle. Twenty patients underwent a general clinical examination, magnetic resonance imaging (MRI), and immune-enzyme testing for biochemical markers of connective tissue injury (pyridinoline and deoxypyridinoline) in urine. Disk dislocation, deformation, adhesion, perforation or squeeze, tension or disruption of ligaments, and injury of articular surfaces are among complications of mandibular fractures that can be revealed on MRI. As regards biochemical findings, we revealed a sharp rise in the levels of pyridinoline and deoxypyridinoline before treatment and a lack of stabilization within 21 days of treatment.

APA, Harvard, Vancouver, ISO, and other styles

40

Smith, Scott M., Jeannie L. Nillen, Adrian LeBlanc, Allan Lipton, Laurence M. Demers, Helen W. Lane, and Carolyn S. Leach. "Collagen Cross-Link Excretion during Space Flight and Bed Rest1." Journal of Clinical Endocrinology & Metabolism 83, no. 10 (October 1, 1998): 3584–91. http://dx.doi.org/10.1210/jcem.83.10.5169.

Full text

Abstract:

Extended exposure to weightlessness results in bone loss. However, little information exists as to the precise nature or time course of this bone loss. Bone resorption results in the release of collagen breakdown products, including N-telopeptide and the pyridinium (PYD) cross-links, pyridinoline and deoxypyridinoline. Urinary pyridinoline and deoxypyridinoline are known to increase during bed rest. We assessed excretion of PYD cross-links and N-telopeptide before, during, and after long (28-day, 59-day, and 84-day) Skylab missions, as well as during short (14-day) and long (119-day) bed-rest studies. During space flight, the urinary cross-link excretion level was twice those observed before flight. Urinary excretion levels of the collagen breakdown products were also 40–50% higher, during short and long bed rest, than before. These results clearly show that the changes in bone metabolism associated with space flight involve increased resorption. The rate of response (i.e. within days to weeks) suggests that alterations in bone metabolism are an early effect of weightlessness. These studies are important for a better understanding of bone metabolism in space crews and in those who are bedridden.

APA, Harvard, Vancouver, ISO, and other styles

41

Stagi, Stefano, Elisabetta Lapi, Eleonora Gambineri, Cristina Manoni, Maurizio Genuardi, Gloria Colarusso, Camilla Conti, Francesco Chiarelli, Maurizio de Martino, and Chiara Azzari. "Bone density and metabolism in subjects with microdeletion of chromosome 22q11 (del22q11)." European Journal of Endocrinology 163, no. 2 (August 2010): 329–37. http://dx.doi.org/10.1530/eje-10-0167.

Full text

Abstract:

IntroductionAlthough hypoparathyroidism with hypocalcaemia is one of the most frequent clinical features of monoallelic microdeletion of chromosome 22q11 (22q11DS), bone mass and metabolism have not yet been assessed in these patients.DesignThis study aimed to evaluate bone mass and metabolism in a cohort of patients, both children and adults, with 22q11DS.MethodsIn twenty-eight patients with 22q11DS (median age 12.5, range 6.1–42.8 years), serum levels of ionised and total calcium, phosphate, parathyroid hormone (PTH), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, osteocalcin and bone-specific alkaline phosphatase (BSAP), and urinary deoxypyridinoline concentrations were evaluated. In these patients, bone mineral density (BMD) was evaluated by dual-energy X-ray absorptiometry (DXA) examination, and volumetric BMD (bone mineral apparent density (BMAD)) was calculated.The data obtained from paediatric and adult patients were compared with two age-, sex- and body size-matched healthy subject control groups.ResultsPatients with 22q11DS showed a reduced BMAD Z-score compared with controls (P<0.001). These patients also had significantly lower ionised (P<0.001) and total calcium (P<0.05) levels as well as lower PTH levels (P<0.05), compared with the controls. In particular, children and young patients with 22q11DS had significantly lower serum osteocalcin levels (P<0.001), BSAP levels (P<0.001) and urinary deoxypyridinoline concentrations (P<0.001) than controls. These results were not confirmed in adults.Finally, patients with hypoparathyroidism and/or hypocalcaemia at the time of the study showed significantly lower ionised (P<0.001) and total calcium levels (P<0.001), PTH levels (P<0.05), BSAP levels (P<0.001), osteocalcin levels (P<0.001) and urinary deoxypyridinoline concentrations (P<0.001), compared with patients without hypoparathyroidism and/or hypocalcaemia. Nonetheless, the BMAD Z-score did not show substantial differences between these two groups.ConclusionsSubjects with 22q11DS have a significant reduction in bone mass that appears to be more severe in adults who have already attained peak bone mass than in children who are still growing. Therefore, we suggest a close monitoring of bone mass and metabolism in 22q11DS patients.

APA, Harvard, Vancouver, ISO, and other styles

42

Savas, I., O. Ural Gurkan, H. Savas, B. E. Gulbay, G. Ugur, and N. Numan. "Urine deoxypyridinoline level…An alternative to bone scan in lung cancer?" Lung Cancer 29, no. 1 (September 2000): 257. http://dx.doi.org/10.1016/s0169-5002(00)80885-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Adamczyk, Maciej, Srinivasa Rao Akireddy, and Rajarathnam E. Reddy. "Versatile synthesis of (+)-deoxypyridinoline, a biochemical marker for diagnosis of osteoporosis." Tetrahedron: Asymmetry 10, no. 16 (August 1999): 3107–10. http://dx.doi.org/10.1016/s0957-4166(99)00329-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Savaş, Ismail, Özlem Ural Gürkan, Hacer Savaş, Banu Eriş, Uğur Gönüllü, and Numan Numanoğlu. "Urine deoxypyridinoline level: an alternative to bone scan in lung cancer?" Clinical Biochemistry 33, no. 7 (October 2000): 591–93. http://dx.doi.org/10.1016/s0009-9120(00)00166-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Waelchli, Rudolf, Ch Beerli, H. Meigel, and L. Révész. "First total synthesis of the bone resorption markers deoxypyridinoline and hydroxypyridinoline." Bioorganic & Medicinal Chemistry Letters 7, no. 22 (November 1997): 2831–36. http://dx.doi.org/10.1016/s0960-894x(97)10084-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Bettica, P., A. K. Taylor, J. Talbot, L. Moro, R. Talamini, and D. J. Baylink. "Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis." Journal of Clinical Endocrinology & Metabolism 81, no. 2 (February 1996): 542–46. http://dx.doi.org/10.1210/jcem.81.2.8636265.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Vanderspank, Dana, Suzanne M. Bernier, Maggie M. Sopper, Patricia Watson, and Michelle F. Mottola. "Activity Restriction Increases Deoxypyridinoline Excretion in Hospitalized High-Risk Pregnant Women." Biological Research For Nursing 16, no. 1 (October 17, 2012): 7–15. http://dx.doi.org/10.1177/1099800412463120.

Full text

Abstract:

Purpose:Activity restriction (AR), one of the most common interventions used in high-risk pregnancies, may exacerbate loss of bone mass. The purpose of this study was to determine changes over time in bone resorption in hospitalized AR women during late pregnancy.Methods:This was a short-term prospective study conducted in two tertiary-care obstetric hospitals. We measured urinary deoxypyridinoline (Dpd) excretion, a marker of bone resorption, once per week in a convenience sample of 14 hospitalized AR women in the third trimester and compared values at 28–31 and 34–36 weeks’ gestation to those of 11 ambulatory control women. Both groups completed a bone-loading questionnaire, 3-day food intake record, and pedometer step counts at the same gestational age.Results:Urinary Dpd excretion increased from Days 1–7 (2.60 ± 0.32 nmol/mmol creatinine) to Days 22–28 (5.36 ± 0.83 nmol/mmol creatinine; p ≤ .05). Dpd excretion was higher in AR women (4.51 ± 0.31 nmol/mmol creatinine) than ambulatory women (2.72 ± 0.39 nmol/mmol creatinine) at 34–36 weeks’ gestation ( p ≤ .05). Energy intake between ambulatory and AR women was not different ( p ≥ .05). All women met the daily requirements for calcium and vitamin D intake during pregnancy. Average daily pedometer steps for the AR women were significantly less compared to controls (1,329 ± 936 and 8,024 ± 1,890 steps/day, respectively; p ≤ .05).Conclusions:AR leads to increased bone resorption in hospitalized pregnant women, which may impact future risk of developing osteopenia and osteoporosis.

APA, Harvard, Vancouver, ISO, and other styles

48

Rauch, F., B. Middelmann, F. Rosmalen, M. J. Seibel, and E. Schönau. "Free deoxypyridinoline in urine and serum — Results in children and adolescents." Experimental and Clinical Endocrinology & Diabetes 104, no. 05 (July 15, 2009): 396–99. http://dx.doi.org/10.1055/s-0029-1211474.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Nakamura, Hirotoshi, Tomoko Mori, Rieko Genma, Yoshikazu Suzuki, Hiroko Natsume, Shinichiro Andoh, Ryo Kitahara, Shinsuke Nagasawa, Kozo Nishiyama, and Teruya Yoshimi. "Urinary excretion of pyridinoline and deoxypyridinoline measured by immunoassay in hypothyroidism." Clinical Endocrinology 44, no. 4 (April 1996): 447–51. http://dx.doi.org/10.1046/j.1365-2265.1996.691513.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Bettica, P. "Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis." Journal of Clinical Endocrinology & Metabolism 81, no. 2 (February 1, 1996): 542–46. http://dx.doi.org/10.1210/jc.81.2.542.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!